These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 21690418)

  • 21. [New antiviral agents against hepatitis C in clinical trials. Hope for a cure--but resistance problems must be overcomed].
    Lennerstrand J; Bondeson K; Bergqvist A; Blomberg J; Oberg B
    Lakartidningen; 2009 Nov 25-Dec 1; 106(48):3254-6, 3258, 3260. PubMed ID: 20101837
    [No Abstract]   [Full Text] [Related]  

  • 22. New HCV drugs trigger race for more tolerable therapies.
    Williams SC
    Nat Med; 2011 Dec; 17(12):1526. PubMed ID: 22146431
    [No Abstract]   [Full Text] [Related]  

  • 23. Protease inhibitors: silver bullets for chronic hepatitis C infection?
    Alkhouri N; Zein NN
    Cleve Clin J Med; 2012 Mar; 79(3):213-22. PubMed ID: 22383557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases.
    Ghany MG; Nelson DR; Strader DB; Thomas DL; Seeff LB;
    Hepatology; 2011 Oct; 54(4):1433-44. PubMed ID: 21898493
    [No Abstract]   [Full Text] [Related]  

  • 25. Triple therapy with first-generation protease inhibitors for patients with genotype 1 chronic hepatitis C: recommendations of the Italian association for the study of the liver (AISF).
    ; Coco B; Caraceni P; Aghemo A; Bitetto D; Bruno R; Ciancio A; Marzioni M; Petta S; Rendina M; Valenti L;
    Dig Liver Dis; 2014 Jan; 46(1):18-24. PubMed ID: 24119482
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New developments in HCV therapy.
    Kronenberger B; Zeuzem S
    J Viral Hepat; 2012 Jan; 19 Suppl 1():48-51. PubMed ID: 22233414
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Triple therapy for hepatitis C.
    Giordano C
    JAAPA; 2012 Feb; 25(2):59-60. PubMed ID: 22416558
    [No Abstract]   [Full Text] [Related]  

  • 28. Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir.
    Swiss Association for the Study of the Liver
    Swiss Med Wkly; 2012; 142():w13516. PubMed ID: 22367957
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prompt arrival of antivirals against hepatitis C for HIV patients.
    Barreiro P; Vispo E
    AIDS Rev; 2010; 12(4):242-3. PubMed ID: 21344779
    [No Abstract]   [Full Text] [Related]  

  • 30. [Novel treatment for chronic hepatitis C in near future].
    Inoue K; Watanabe T; Yamada M; Yoshiba S
    Nihon Shokakibyo Gakkai Zasshi; 2009 Apr; 106(4):493-501. PubMed ID: 19346717
    [No Abstract]   [Full Text] [Related]  

  • 31. The FDA, bridging data, and hepatitis C.
    Fried MW; Jensen DM
    Hepatology; 2013 Mar; 57(3):875-7. PubMed ID: 23456679
    [No Abstract]   [Full Text] [Related]  

  • 32. Hepatitis C virus treatment: the unyielding chasm between efficacy and effectiveness.
    Kanwal F; El-Serag HB
    Clin Gastroenterol Hepatol; 2014 Aug; 12(8):1381-3. PubMed ID: 24607698
    [No Abstract]   [Full Text] [Related]  

  • 33. Letter: Telaprevir triple therapy in chronic hepatitis C genotype 1 patients receiving haemodialysis.
    Wiegand J; Maasoumy B; Buggisch P; Buslau A; Schiefke I; Berg T; Wedemeyer H; Sarrazin C; Hinrichsen H
    Aliment Pharmacol Ther; 2014 Jun; 39(11):1342-4. PubMed ID: 24803258
    [No Abstract]   [Full Text] [Related]  

  • 34. Preparation of HCV infected patients to the triple therapy with first generation protease inhibitors.
    Kozielewicz D; Halota W; Dybowska D
    Przegl Epidemiol; 2013; 67(4):623-8,713-6. PubMed ID: 24741907
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A major advance in treating hepatitis C.
    Johns Hopkins Med Lett Health After 50; 2011 Dec; 23(10):6. PubMed ID: 22216468
    [No Abstract]   [Full Text] [Related]  

  • 36. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C.
    Jacobson IM; Pawlotsky JM; Afdhal NH; Dusheiko GM; Forns X; Jensen DM; Poordad F; Schulz J
    J Viral Hepat; 2012 May; 19 Suppl 2():1-26. PubMed ID: 22404758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of boceprevir: a first-in-class direct antiviral treatment for chronic hepatitis C infection.
    Hazuda DJ; Burroughs M; Howe AY; Wahl J; Venkatraman S
    Ann N Y Acad Sci; 2013 Jul; 1291():69-76. PubMed ID: 23859802
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir.
    Marks KM; Jacobson IM
    Antivir Ther; 2012; 17(6 Pt B):1119-31. PubMed ID: 23188750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Cost-effectiveness and safety of telaprevir and boceprevir for chronic hepatitis C in real-world clinical practice].
    Giménez-Manzorro Á; García-González X; Rodríguez-González CG; Ochoa-Palominos A; Sanjurjo-Sáez M; Clemente-Ricote G
    Gastroenterol Hepatol; 2015 Dec; 38(10):575-82. PubMed ID: 26321320
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resistance to anti-HCV protease inhibitors.
    Thompson AJ; Locarnini SA; Beard MR
    Curr Opin Virol; 2011 Dec; 1(6):599-606. PubMed ID: 22440917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.